Evidence map›Paper›PMID 40237483›Full record

ArticlemSphere2025

Meningococcal vaccine 4CMenB elicits a robust cellular immune response that targets but is not consistently protective against

Joseph J Zeppa, Jamie E Fegan, Pauline Maiello, Epshita A Islam, Isaac S Lee, Christine Pham, Laura-Lee Caruso, Scott D Gray-Owen

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in mSphere, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Review
  8. Review
  9. Article
  10. Protection againstFrontiers in immunology · 2025
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

8 authors.

Joseph J ZeppaDepartment of Molecular Genetics, Temerty Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada.ORCID 0000-0003-1136-4793
Jamie E Fegan *Department of Molecular Genetics, Temerty Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada.
Pauline Maiello *Department of Microbiology and Molecular Genetics, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.
Epshita A Islam *Department of Biochemistry, University of Toronto, Toronto, Ontario, Canada.
Isaac S LeeDepartment of Molecular Genetics, Temerty Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada.
Christine PhamDepartment of Molecular Genetics, Temerty Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada.
Laura-Lee CarusoDepartment of Molecular Genetics, Temerty Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada.
Scott D Gray-OwenDepartment of Molecular Genetics, Temerty Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada.ORCID 0000-0002-1477-3616

Funding

Using gonococcal TonB-dependent transporters as vaccine antigensU19AI144182 · NIAID · GEORGIA STATE UNIVERSITY · PI CORNELISSEN, CYNTHIA N · 2019 to 2023
$9.3M
CIHR PJT-153177NIAID NIH HHS U19 AI144182NIH HHS 1U19AI144182-01
6 · The paper itself

Abstract

Retrospective epidemiological studies suggest that the licensed serogroup B meningococcal vaccine 4CMenB (Bexsero) provides some protection against the closely related pathogen

Indexed as

GonorrheaImmunity, CellularMeningococcal VaccinesNeisseria gonorrhoeaeVaginal DiseasesAnimalsAntibodies, BacterialDisease Models, AnimalFemaleMiceMice, Inbred C57BLVagina4CMenB vaccineAntibodies, BacterialMeningococcal Vaccines4CMenBadaptive immunityBexseroNeisseria gonorrhoeaeT-cell immunity

Identifiers

PMID40237483
PMCPMC12108064

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.